Trump Administration Reschedules Marijuana, Removing 280E Tax Burden
Event summary
- The U.S. Trump Administration has rescheduled medical marijuana to Schedule III under the Controlled Substances Act.
- This reclassification, finalized April 23, 2026, follows a rulemaking process initiated in 2024.
- The move removes Section 280E, the punitive tax burden previously applied to Schedule I and II substances.
- The rescheduling allows for expanded medical research utilizing products already available through state-licensed operators.
- The Attorney General initiated a further rulemaking process, anticipating an expedited timeline and a hearing this summer.
The big picture
The rescheduling represents a significant shift in federal cannabis policy, potentially unlocking substantial research and financial benefits for companies like Trulieve. While not legalization, this move aligns federal law more closely with state-level practices and creates a more favorable operating environment. The ongoing rulemaking process suggests further policy adjustments are likely, creating both opportunities and uncertainties for the industry.
What we're watching
- Regulatory Headwinds
- The expedited rulemaking process announced alongside the rescheduling carries uncertainty; the summer hearing will be a key indicator of the final scope of changes.
- Research Impact
- The extent to which increased research funding and clinical trials translate into tangible product innovation and market expansion for Trulieve remains to be seen.
- Financial Impact
- The removal of Section 280E will improve Trulieve’s profitability, but the magnitude of the impact will depend on the company’s current tax burden and overall financial health.
Related topics